Rutin and Omega-6 Composition for 5-Alpha-Reductase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for androgenetic alopecia, such as finasteride, come with side effects like reduced libido and allergic reactions, and natural alternatives like Boehmeria nivea extracts pose allergy risks, necessitating a safer, effective composition for hair growth and sebum regulation.
Innovation Solution
A composition combining omega-6 polyunsaturated fatty acids and rutin, which are commercially available and of natural origin, to inhibit 5-alpha-reductase activity, reducing the risk of allergic reactions and providing effective hair growth and sebum regulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If finasteride is used to inhibit 5-alpha-reductase, then hair growth is promoted and sebum production is regulated, but side effects such as reduced libido, impotence, and allergic reactions occur
Solution Approach 1:
The patent replaces the synthetic finasteride molecule with a natural plant extract from Boehmeria nivea, which achieves the same 5-alpha-reductase inhibition effect without the harmful side effects. The natural extract acts as a temporary, renewable alternative that does not accumulate harmful effects in the body.
Solution Approach 2:
The patent introduces an intermediary substance - the Boehmeria nivea extract - which mediates between the need for 5-alpha-reductase inhibition and the avoidance of side effects. This natural extract contains active principles that selectively inhibit the enzyme without triggering the adverse reactions associated with synthetic finasteride.
2Object-affected harmful factors
If Boehmeria nivea extract is used as a natural alternative, then allergic reactions are reduced, but the risk of allergy remains for subjects with atopic asthma
Solution Approach 1:
The patent extracts and isolates the specific active principles responsible for 5-alpha-reductase inhibition from the Boehmeria nivea plant, separating them from the allergenic components. This allows the therapeutic effect to be maintained while removing or minimizing the substances that cause allergic reactions in atopic subjects.
Solution Approach 2:
The patent modifies the chemical composition parameters of the plant extract by isolating specific active principles and removing allergenic components. This parameter change transforms the extract from a potentially allergenic substance to a safer therapeutic agent that maintains efficacy while reducing immunogenicity.
3Reliability
If synthetic inhibitors like finasteride are used, then 5-alpha-reductase activity is strongly inhibited, but the treatment complexity and contraindications increase
Solution Approach 1:
The patent uses a composite natural extract containing multiple active principles from Boehmeria nivea that work synergistically to inhibit 5-alpha-reductase. This composite natural material achieves the desired enzymatic inhibition while avoiding the complex contraindications associated with single-molecule synthetic inhibitors like finasteride.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of omega-6 polyunsaturated fatty acids and rutin effectively inhibits 5-alpha-reductase, reducing DHT levels, promoting hair growth, regulating sebum production, and minimizing allergic reactions, offering a safer alternative to existing treatments.
Implementation Method 1
Active substances have therefore been studied which, by blocking or reducing the activity of 5-alpha-reductase, cause a decrease in the levels of DHT
Data Source
AI summary
The present invention relates to the use of selected active principles of a natural origin in substitution of extract from Boehmeria Nipononivea for regulating the trophism of hair follicles and the production of sebum on the skin and its use in alopecia, with considerable practical advantages and with respect to the safety profile.The composition of the invention is based on an association of omega 6 polyunsaturated acids and rutin in a pharmaceutically acceptable carrier.